רוקחות-פרמקולוגיה

EHA: French Compassionate-Use Experience With Trisenox (Arsenic Trioxide) Injection Confirms Previously Reported Efficacy, Safety Seen In United States

FLORENCE, ITALY — June 7, 2002 —

Cell Therapeutics (UK) Limited, a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI), announced that Trisenox® (arsenic trioxide) injection induced complete remission (CR) in 75 percent of the initial patients with relapsed or refractory acute promyelocytic leukemia (APL) who received the drug in a compassionate-use program in France.

 The findings were announced today in a presentation (poster no. 520) given during the 7th Congress of the European Hematology Association (EHA) in Florence, Italy. “Trisenox is proving to be a remarkable advancement in the treatment of relapsed/refractory APL, and we are eager for it to become available in France,” said Pierre Fenaux, M.D., Professor of Hematology at University Hospital in Lille, France.

“The experience to date with APL patients in France demonstrates that Trisenox has great promise for the induction, consolidation, and possibly maintenance of complete remission in relapsed APL patients.” CTI was granted authorization from the European Commission earlier this year to market Trisenox in the European Union.

To date, more than 1,000 patients have participated in Trisenox multinational clinical trials or have been treated with the product since it was approved for marketing in the United States in 2000.

“The results observed in this compassionate use program in France confirm our experience with Trisenox in the United States, where the drug has become the standard of care for relapsed APL patients,” said Carolyn Paradise, M.D., chief medical officer at CTI.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר